Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema

NCT00133952 is registered in ClinicalTrials.gov with Chromaderm, Inc. as lead sponsor.

NCT NCT00133952
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00133952 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Lead sponsor
Chromaderm, Inc.
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2005
Completion date
July 31, 2011
Enrollment
309 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema